Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study
Masahiko Shimura, Shigehiko Kitano, Daisuke Muramatsu, et all.
Background/Aims To investigate real-world outcomes for best-corrected visual acuity (BCVA) after 2-year clinical intervention for treatment-naïve, centr-involving diabetic macular oedema (DME).
Methods Retrospective analysis of longitudinal medical records obtained from 27 institutions specialising in retinal diseases in Japan. A total of 2049 eyes with treatment-naïve DME commencing intervention between 2010 and 2015 who were followed for 2 years were eligible. Interventions for DME included anti-vascular endothelial growth factor (VEGF) therapy, local corticosteroid therapy, macular photocoagulation and vitrectomy. Baseline and final BCVA (logMAR) were assessed. Eyes were classified by the treatment pattern, depending on whether anti-VEGF therapy was used, into an anti-VEGF monotherapy group (group A), a combination therapy group (group B) and a group without anti-VEGF therapy (group C).
Results The mean 2-year improvement of BCVA was −0.04±0.40 and final BCVA of >20/40 was obtained in 46.3% of eyes. Based on the treatment pattern, there were 427 eyes (20.9%) in group A, 807 eyes (39.4%) in group B and 815 eyes (39.8%) in group C. Mean improvement of BCVA was −0.09±0.39, –0.02±0.40 and −0.05±0.39, and the percentage of eyes with final BCVA of >20/40 was 49.4%, 38.9%, and 52.0%, respectively.
Conclusion Following 2-year real-world management of treatment-naïve DME in Japan, BCVA improved by 2 letters. Eyes treated by anti-VEGF monotherapy showed a better visual prognosis than eyes receiving combination therapy. Despite treatment for DME being selected by specialists in consideration of medical and social factors, a satisfactory visual prognosis was not obtained, but final BCVA remained >20/40 in half of all eyes.
Role of internal limiting membrane peeling in the prevention of epiretinal membrane formation following vitrectomy for retinal detachment: a randomised trial
Vinod Kumar, Devashish Dubey, Kumawat, Ashish Markan, Parijat Chandra, Mahesh Chandra, Atul Kumar
Aim To study the role of internal limiting membrane (ILM) peeling in the prevention of macular epiretinal membrane (ERM) formation following pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment (RRD).
Methods In a randomised trial, patients with macula-off RRD (duration ≤3 months) with proliferative vitreoretinopathy grade ≤C1 and absence of pre-existing maculopathy were recruited from June 2016 to May 2018. Patients were randomised into two groups: group 1 (conventional treatment) underwent PPV alone, while group 2 underwent PPV with macular ILM peeling. The main outcome measures were macular ERM formation (detected on optical coherence tomography), corrected distance visual acuity (CDVA), retinal attachment and central macular thickness (CMT) at last follow-up (minimum 6 months).
Results Sixty patients (30 in each group) completed the required follow-up. The two groups were comparable in sex distribution, age, duration of RRD, baseline CDVA and duration of follow-up (median 15.5 vs 14 months). Macular ERM developed in 20% (n=6) and 0% of eyes in groups 1 and 2, respectively (p=0.002). Retinal reattachment was attained in all eyes. There was no statistical difference in final CDVA between the groups (p=0.43). Dissociated optic nerve fibre layer (DONFL) was found in 0% and 40% (n=12) of eyes in groups 1 and 2, respectively (p=0.0001). However, DONFL did not significantly affect the final CDVA (p=0.84). The final CMT was 266.0±37.5 µm and 270.0±73.7 µm in groups 1 and 2, respectively, with no statistical difference (p=0.62).
Conclusions ILM peeling prevents macular ERM formation following PPV for RRD but provides similar visual outcomes as compared with conventional treatment.
Prediction of visual outcomes by an artificial neural network following intravitreal injection and laser therapy for retinopathy of prematurity
Ching-Yen Huang, Ren-Jieh Kuo, Cheng-Han Li, Daniel S Ting, Eugene Yu-Chuan Kang, Chi-Chun Lai,Hsiao-Jung Tseng, Lan-Yan Yang
Aims To construct a program to predict the visual acuity (VA), best corrected VA (BCVA) and spherical equivalent (SE) of patients with retinopathy of prematurity (ROP) from 3 to 12 years old after intravitreal injection (IVI) of anti-vascular endothelial growth factor and/or laser photocoagulation treatment.
Methods This retrospective study employed a feedforward artificial neural network with an error backpropagation learning algorithm to predict visual outcomes based on patient birth data, treatment received and age at follow-up. Patients were divided into two groups based on prior treatments. The main outcome measures were the difference between the predicted and actual values of visual outcomes. These were analysed using the normalised root mean square error (RMSE). Two-way repeated measures analysis of variance was used to compare the predictive accuracy by this algorithm.
Results A total of 60 ROP infants with prior treatments were included. In the IVI group, the normalised average RMSE for VA, BCVA, and SE was 0.272, 0.185 and 0.131, respectively. In the laser group, the normalised average RMSE for VA, BCVA and SE was 0.190, 0.250 and 0.104, respectively. This result shows that better predictive power was obtained for SE than for VA or BCVA in both the IVI and laser groups (p<0.001). In addition, the algorithm performed slightly better in predicting visual outcomes in the laser group (p<0.001).
Conclusions This algorithm offers acceptable power for predicting visual outcomes in patients with ROP with prior treatment. Predictions of SE were more precise than predictions of for VA and BCVA in both groups.